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Clonal amplification of Fasciola hepatica in
Galba truncatula: within and between
isolate variation of triclabendazole-
susceptible and -resistant clones
Jane E. Hodgkinson1* , Krystyna Cwiklinski1,2, Nicola Beesley1, Catherine Hartley1, Katherine Allen1
and Diana J. L. Williams1
Abstract
Background: Fasciola hepatica is of worldwide significance, impacting on the health, welfare and productivity of
livestock and regarded by WHO as a re-emerging zoonosis. Triclabendazole (TCBZ), the drug of choice for controlling
acute fasciolosis in livestock, is also the drug used to treat human infections. However TCBZ-resistance is now
considered a major threat to the effective control of F. hepatica. It has yet to be demonstrated whether F.
hepatica undergoes a genetic clonal expansion in the snail intermediate host, Galba truncatula, and to what
extent amplification of genotypes within the snail facilitates accumulation of drug resistant parasites. Little is
known about genotypic and phenotypic variation within and between F. hepatica isolates.
Results: Six clonal isolates of F. hepatica (3× triclabendazole-resistant, TCBZ-R and 3× triclabendazole-susceptible, TCBZ-S)
were generated. Snails infected with one miracidium started to shed cercariae 42–56 days post-infection and
shed repeatedly up to a maximum of 11 times. A maximum of 884 cercariae were shed by one clonally-infected snail
(FhLivS1) at a single time point, with > 3000 clonal metacercariae shed over its lifetime. Following experimental
infection all 12 sheep were FEC positive at the time of TCBZ treatment. Sheep infected with one of three putative
TCBZ-S clones and treated with TCBZ had no parasites in the liver at post-mortem, whilst sheep each infected with
putative TCBZ-R isolates had 35–165 adult fluke at post-mortem, despite TCBZ treatment. All six untreated control
animals had between 15–127 parasites. A single multi-locus genotype was reported for every fluke from each of the six
clonal isolates. Adult F. hepatica showed considerable variation in weight, ranging from 20–280 mg, with variation in
weight evident within and amongst clonal isolates.
Conclusions: A genetic clonal expansion occurs within G. truncatula, highlighting the potential for amplification of
drug resistant genotypes of F. hepatica. Variation in the weight of parasites within and between clonal isolates and
when comparing isolates that are either susceptible or resistant to TCBZ represent inherent variation in liver fluke and
cannot be attributed to their resistance or susceptibility traits.
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Background
Fasciola hepatica is a trematode parasite of worldwide
significance. A commonly diagnosed helminth parasite
in sheep and cattle it is increasing in prevalence and
spreading into new areas [1, 2] and is regarded by the
WHO as a re-emerging zoonosis, with an estimated 17
million people at risk of infection [3]. It has a two-host
life-cycle involving a mammalian definitive host, typic-
ally sheep and cattle, and a molluscan intermediate host,
predominantly Galba truncatula in the UK and across
western Europe. Following embryonation of F. hepatica
eggs shed in the faeces of an infected host, the miracidia
hatch and infect the snail, where parasite amplification
occurs prior to shedding of multiple cercariae ~6–8
weeks post-infection. These cercariae encyst on vegeta-
tion as metacercariae; the infective stage that is subse-
quently ingested by the definitive host. On ingestion of
metacercariae the newly excysted juvenile (NEJ) stage
migrates through the liver and can cause disease known
as acute fasciolosis, a significant cause of morbidity and
mortality in livestock, particularly sheep. Temperature
and rainfall are the principle determinants affecting the
life-cycle and hence the prevalence and intensity of F.
hepatica infection [2]. It is suggested that climate change
is at least partly responsible for the increase in the
prevalence of F. hepatica [4] and is thought to exacer-
bate the financial and welfare impact of fasciolosis on
livestock production [5].
Triclabendazole (TCBZ), a key compound in the con-
trol of acute fasciolosis in livestock due to its efficacy
against NEJ as early as two days post-infection [6], is
also the drug of choice to treat human fasciolosis. The
heavy reliance on TCBZ to treat sheep and cattle at fre-
quent intervals has resulted in the emergence of
TCBZ-resistance first in Australia and subsequently in
many other countries [7–9]. It is now considered a
major threat to the effective control of F. hepatica
worldwide [10, 11]. The genetic and molecular basis of
TCBZ resistance remains unknown. Linkage mapping
for drug resistance has proved highly successful for
protozoan parasites, for example malaria and Eimeria
[12], and for trematodes such as Schistosoma mansoni
[13, 14]. These mapping exercises rely on access to a
number of specific resources; a high quality genome as-
sembly and linkage map [15] and the availability of
clonal isolates. Significant advances have been made re-
cently with publication of the first draft of the F. hepat-
ica genome in 2015 [16] and work is underway to
enhance its assembly. To date the majority of TCBZ
resistance studies have been conducted on laboratory
isolates, for example, the TCBZ-susceptible (TCBZ-S)
Fairhurst and Cullompton isolates and TCBZ-resistant
(TCBZ-R), Sligo and Oberon isolates [17, 18]; which were
isolated from the field more than a decade ago [19, 20].
The need to routinely confirm the susceptibility of isolates
used in drug resistance and drug development trials was
highlighted recently [21]. At the genetic level, all currently
available fluke isolates are either not characterised or at
best are only partially genetically defined. A source of ge-
notypically characterised clonal lines, phenotypically de-
fined for their sensitivity to key drugs like TCBZ, is
essential to the success of forward genetic approaches that
have proved so successful in mapping drug resistance loci
in other parasites [14, 21, 22].
Here, we report the production of six clonal isolates
by experimental infection of G. truncatula with a single
miracidium derived from one of five field isolates and
one laboratory maintained isolate of F. hepatica
(Shrewsbury isolate, Ridgeway Research Ltd). Clonal iso-
lates were phenotypically defined for their sensitivity to
TCBZ by experimental infection in sheep and subse-
quent treatment with TCBZ at the recommended dose
rate of 10 mg/kg. Genotyping of each isolate was carried
out using a F. hepatica microsatellite panel [23]. These
neutral markers were used to confirm the capacity for
genetically clonal amplification of F. hepatica within G.
truncatula and provided a multilocus genotype (MLG)
with which to uniquely identify each clonal isolate.
Methods
Source of eggs for Fasciola hepatica clonal isolates
Six clonal isolates of F. hepatica, 3× TCBZ-R and 3×
TCBZ-S, were generated. For the TCBZ-R isolates, three
field isolates of F. hepatica were sourced from naturally
infected sheep with a history of TCBZ treatment:
FhLivR1, Northwest England, UK; FhLivR2, South
Wales, UK and FhLivR3, Northwest England, UK (a lo-
cation distinct from FhLivR1). For the TCBZ-S isolates,
two field isolates were sourced from naturally infected
sheep not previously exposed to TCBZ; FhLivS2, North-
west England, UK and FhLivS3, Southwest England, UK.
An additional isolate, FhLivS1, was sourced from cattle
experimentally infected with the laboratory maintained
TCBZ-S Shrewsbury isolate (Ridgeway Research Ltd,
UK). Eggs were recovered from the gall bladder of in-
fected sheep/purged from F. hepatica adult parasites at
post-mortem (FhLivS1, FhLivR1 and FhLivR3) or isolated
from faecal samples using a standard sedimentation
method (FhLivS2, FhLivS3, FhLivR2).
Maintenance and experimental infection of G. truncatula
and production of F. hepatica metacercariae
Galba truncatula snail stocks were maintained on pans
of clay mud and fed on a diet of Oscillatoria spp. algae.
Both the snails and algae were maintained at a con-
trolled temperature of 22 °C. For experimental infection
of snails, F. hepatica eggs were embryonated at 27 °C in
the dark for 14 days followed by exposure to a direct
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light source to stimulate hatching of miracidia. A single
miracidium was co-incubated with an individual snail of
approximately 4 mm in height in each well of a 48-well
plate in ~200 μl of H2O + ~100 μl algae and incubated
for a minimum of 4 h. Following infection, snails were
maintained on mud pans and fed every 2–3 days. At 6
weeks post-infection (wpi), individual snails were sealed
in visking tubing containing H2O and stimulated to shed
cercariae by exposing snails to a drop in temperature to
12 °C for 30 min followed by a slow return to RT under
a light source over a period of several hours. They were
then left overnight to allow metacercariae to encyst on
the visking tubing. Metacercariae were subsequently
stored at 4 °C. Individual snails were shed repeatedly
and metacercariae from each individual snail were
pooled prior to infection of sheep.
Experimental infection of sheep and recovery of adult
parasites at post-mortem
Typically, experimental infections were carried out using
lambs ~3 months of age that had no access to pasture.
Animals were housed in group conditions in an indoor
facility and fed on growing sheep concentrate pellet with
hay and water provided ad libitum. Lambs were
inspected at least daily for the duration of the sampling
period. Prior to infection lambs were confirmed free of
F. hepatica infection by antibody detection ELISA using
F. hepatica ES antigens ELISA [24] and faecal egg count
(FEC) using a standard sedimentation technique. Infec-
tions were performed by oral administration of metacer-
cariae to two sheep per isolate using a dose of ~200
clonal metacercariae per sheep. The viability of metacer-
cariae was assessed prior to infection by visualising
flame cells, if no flame cells were seen the metacercariae
were considered to be non-viable. One sheep from each
pair was treated with TCBZ at the recommended dose
rate of 10 mg/kg, whilst the other sheep remained as an
untreated control. All sheep were euthanized 10 days
post-TCBZ treatment (time of euthanasia was different
for each clone and ranged from 17–24 wpi). Infection
status was monitored weekly by ELISA from four weeks
prior to infection until post-mortem or by FEC from,
pre-infection and then from eight wpi until necropsy. At
post-mortem liver flukes were manually recovered dir-
ectly by dissection from the bile ducts or following sli-
cing of the liver and incubation in PBS for 2 h at 37 °C.
Eggs were harvested from adult parasites purged by in-
cubation in 1–2 ml of Dulbecco’s Modified Eagle’s Media
(DMEM; Sigma-Aldrich, Dorset, UK) for a minimum of
2 h at 37 °C. The parasites were then removed from the
culture medium, whole parasites were weighed and all
fluke material (including partial fluke) was snap frozen
in liquid nitrogen. Purged eggs were stored at 4 °C;
batches were periodically embryonated as described
above and passaged through snails and sheep to main-
tain clonal lines.
Genotyping of clonal isolates
The entire adult fluke or a section of adult fluke near
the anterior sucker, representing 20 mg of tissue was
used for DNA extraction. Genomic DNA extraction was
carried out using the DNeasy Blood and Tissue Kit (for
20 mg tissue) or Genomic tip 100G (for whole adult
fluke) (both Qiagen, Manchester, UK), according to the
manufacturer’s instructions. For the majority of samples
this was followed by an ethanol precipitation and
re-suspension of DNA in a volume of 60 μl TE (pH 8.0).
All DNA concentrations were calculated using the
Quant-iTTM PicoGreen® dsDNA assay kit (Life Tech-
nologies, Thermo Fisher Scientific, Rugby, UK). Micro-
satellite PCR and sequencing was essentially carried out
as described [23, 25] by employing the multiplex proto-
col using the Type-it Microsatellite PCR kit (Qiagen,
UK) according to the manufacturer’s instructions and 1
μl (10 ng) of adult genomic DNA template. PCR prod-
ucts were analysed by agarose gel electrophoresis (2%
gel) using SYBR® Safe DNA stain (Life Technologies). If
a positive result was obtained by gel electrophoresis, the
PCR products were diluted 25 or 50 fold and 1 μl of this
dilution multiplexed in Hi-Di Formamide (8.8 μl; Life
Technologies) with GeneScan LIZ500 size standards (0.2
μl; Life Technologies), prior to sequencing using a 3100
Genetic Analyzer capillary electrophoresis system (Life
Technologies) and Peak Scanner v1.0 software.
Results
Clonal amplification of Fasciola hepatica in Galba
truncatula
Five clonal isolates were derived using populations of
eggs from naturally infected UK sheep flocks, from
one of several geographical locations (Table 1). Low
rates of infection in snails and high mortality of in-
fected snails commonly occurs in experimental sys-
tems, hence, to generate the six clonal isolates
multiple individual snail:miracidium infections were
set up for each population; with a total of between
30–40 snails clonally infected per isolate. Infected
snails were first detected to be shedding cercariae
from 42–56 days post-infection (dpi). Although some
snails shed once and died, the majority (75–89.6%)
continued to shed cercariae multiple times up to a
maximum of 11 times. A snail infected with one
miracidium can generate large numbers of cercariae,
with one snail producing > 3000 clonal metacercariae
(Table 2). Infected snails shed vastly different num-
bers of cercariae over their lifetime with a maximum
of 884 cercariae shed by any one snail at a given
time-point (data not shown). The snail shedding the
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largest number of cercariae was selected from each
population and a subset of ~400 metacercariae de-
rived from this clonally-infected snail was used to in-
fect the two sheep for each clonal isolate (~200
metacercariae per sheep). A single MLG was reported
for every fluke from each of the six isolates (Table 4),
uniquely identifying each clone. The presence of fluke
of just a single genotype in each animal (or pair of
animals infected with metacercariae derived from the
same snail) confirmed a genetic clonal expansion had
occurred in the snail and a clonal infection was estab-
lished in the definitive host.
Phenotyping of TCBZ-susceptible and TCBZ-resistant
clonal isolates of Fasciola hepatica
All three populations from which TCBZ-R clonal isolates
were generated, were from cases referred by the farmer
to the Veterinary Investigation Centre, Camarthen,
Wales, UK (AHVLA, now called the Animal and Plant
Health Agency, APHA); they were cases of suspected
TCBZ resistance, due to therapeutic drug failure or
death of sheep post-TCBZ treatment.
Prior to experimental infection all animals recorded
negative FEC values and for those animals tested by
ELISA (FhLivS1-S3) low percent positivity (PP) values
Table 1 Details of field samples used to generate six Fasciola hepatica clonal isolates
Clonal
isolate
Origin of F. hepatica eggs Geographical location
of farm
History of TCBZ exposure
FhLivR1 Purged from adult parasites recovered at PM
(AHVLA)
North West England Frequent use of TCBZ, treated with TCBZ 28 days prior to
PM and 2 days prior to PM. Sheep died 2 days post-treatment
FhLivR2 Isolated from faecal sample taken 21 days post-TCBZ
treatment
South Wales Population of F. hepatica showing 98.2% reduction based
on FECRTa
FhLivR3 Purged from adult parasites recovered at PM
(AHVLA)
North West England
(not same farm as R1)
History of TCBZ treatment failure on farm, last exposed to
TCBZ 4 months prior to PM
FhLivS1 Shrewsbury laboratory isolate, commercially available
TCBZ susceptible population (Ridgeway Research Ltd,
UK)
Isolated 2006 from
West England
Population of F. hepatica showing TCBZ efficacyb of 97%
in sheep (n = 9), Ridgeway Research Ltd (pers. comm.)
FhLivS2 Isolated from faecal samples from organic sheep
farm
North West England
(not same farm as R1
or R3)
None
FhLivS3 Isolated from faecal samples from organic sheep
farm
South West England Population of F. hepatica showing TCBZ efficacyb of 97.2%
in sheep (n = 12, data not shown)
aTCBZ-S based on criteria for faecal egg count reduction test (FECRT) [45]
bTCBZ % efficacy defined based on critical test performed at 10 days after treatment and using the following calculation: % efficacy = (mean of F. hepatica in
control group – mean of F. hepatica in treated group/ mean of F. hepatica in control group) × 100 [46]
Abbreviations: PM post-mortem, AHVLA/APHA Animal Health Veterinary Laboratory Agency/Animal and Plant Health Agency, TCBZ triclabendazole
Table 2 Experimental infection of sheep for production of Fasciola hepatica clonal isolates
Clonal
isolate
Total no. of cercariae shed by a single snail used to
derive clonal infections
No. of metacercariae used for
infection
Timepoint of PM
(wpi)
No. of adult flukes
recovered at PMa
FhLivR1 931 150 18 70
220 18 165 (T)
FhLivR2 553 193 18 31
200 18 48 (T)
FhLivR3 812 256 18 35 (T)
FhLivS1 3200 209 19 15
224 19 0 (T)
FhLivS2 > 417b 215 24 113
202 24 0 (T)
FhLivS3 1166 200 17 127
200 17 0 (T)
aTwo sheep were infected for each isolate and the dose of metacercariae given to each sheep is shown. Patency of infection was confirmed by faecal egg count
and one sheep from each pair was treated with 10 mg/kg triclabendazole (T) 10 days prior to post-mortem (PM) with the exception of FhLivR3 where one sheep
had to be euthanized during the course of the experiment. The number of adult flukes recovered from each sheep at PM is shown
bActual number not calculated
Abbreviations: wpi weeks post infection, PM post-mortem
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were recorded (0.2–6.5). A single dose of between 150–
256 metacercariae from a single snail exposed to one
miracidia was administered to two animals (see Table 2).
All animals were seropositive by 4 wpi (ELISA PP values
ranged from 18.3–54.4) and were FEC positive by 10 wpi
and eggs were consistently shed by all sheep until the
day of treatment. The sheep recording the highest egg
count was treated with TCBZ at 10 mg/kg whilst the
other remained untreated (Table 3). All 12 sheep were
FEC positive on the day of treatment (Table 3) consist-
ent with the presence of egg producing adult parasites at
the time of TCBZ treatment. Sheep infected with
FhLivS1, S2 or S3 and treated with TCBZ had no adult
liver fluke present at post-mortem, whilst TCBZ treated
sheep infected with FhLivR1, R2 or R3 had fluke bur-
dens ranging from 35–165 (Tables 3, 4). All six un-
treated control animals had liver fluke burdens with
between 15–127 parasites per sheep (Table 2). This con-
firmed the resistant or susceptible phenotype of each
isolate. The adult F. hepatica from each isolate showed
considerable variation in the size of fluke both within
and between clonal isolates, although it was not practical
to measure the size of individual adult fluke. This was
reflected in their weight; the larger the fluke the greater
the weight. A minimum weight of 20 mg (FhLivR1 iso-
late) and a maximum weight of 280 mg (FhLivS3) was
found. This variation was evident not only between
clonal isolates but within each clonal isolate (Table 4).
Genotyping of TCBZ-susceptible and TCBZ-resistant clonal
isolates of Fasciola hepatica
A high level of genetic differentiation was observed be-
tween isolates. The MLG for each isolate was distinct and
a number of alleles were unique to each isolate, in particu-
lar loci Fh_2, Fh_4, Fh_5, Fh_6 and Fh_11 were repre-
sented by a different genotype for each isolate (Table 5).
Discussion
Clonal isolates allow us to better understand Fasciola
hepatica biology
To date, no study has analysed F. hepatica parasites at
the molecular level following their expansion within the
snail intermediate host. The presence of multiple adult
parasites of the same MLG, within a host exposed to
metacercariae from a single snail infected with just one
miracidium, is consistent with the clonal amplification
of F. hepatica within G. truncatula. Studies on closely
related trematodes, including Clonorchis sinensis,
Opisthorchis viverrini and Schistosoma spp., have used
molecular tools to demonstrate a genetic clonal amplifi-
cation occurs within the snail intermediate host and
have shown that mitotic recombination events can occur
[26–28]; however, based on our analysis here there is no
evidence to support mitotic recombination in F.
hepatica.
It is difficult to compare published studies of snail in-
fections with F. hepatica, given that husbandry and diet
can affect cercarial output [29, 30], but the experimental
infection of snails performed here adds valuable insights
into the capacity of snails to shed cercariae. The time
from when snails were exposed to miracidia to the first
observation of cercarial shedding is similar to previous
studies [31–33]. However, the period of cercarial shed-
ding by experimentally infected snails exceeds that re-
ported elsewhere [31–34], but is similar to that of
Hodasi et al. [35], where snails were fed the same diet
(Oscillatoria spp.). The mean number of metacercariae
produced by snails infected with a single miracidium has
been reported as 114.9 (SD: 80.3) [32], which is lower
than observed with our snails, probably due to the ex-
tended period over which our infected snails shed cer-
cariae. As with other studies we observed that some
snails are ‘super-shedders’ producing thousands of meta-
cercariae [35].
Table 3 Faecal egg count and adult parasite burden at post-mortem for six Fasciola hepatica clonal isolates. Two sheep were
infected for each clonal isolate, patency of infection was confirmed by faecal egg count (FEC), expressed as eggs per gram (epg).
One sheep from each pair was treated with 10mg/kg triclabendazole, the other sheep was left untreated. After 10 days all sheep
were euthanised and adult liver fluke were enumerated post-mortem
Clonal
isolate
FEC (epg) on day of treatment Number of adult liver flukes present post-mortem
TCBZ+ TCBZ- TCBZ+ TCBZ-
FhLivR1 381 137 165 70
FhLivR2 324 50 48 31
FhLivR3a 186 – 35 –
FhLivS1 6 2 0 15
FhLivS2 146 57 0 127
FhLivS3 89 73 0 113
aFhLivR3, one sheep (TCBZ-) had to be euthanized for non-fluke related illness during the course of the experiment
Abbreviations: epg eggs per gram, FEC faecal egg count; TCBZ+, treatment with 10 mg/kg triclabendazole; TCBZ-, no treatment with 10 mg/kg triclabendazole
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Gene flow is driven by multiplication and recombin-
ation events in the intermediate and definitive hosts, re-
spectively. The genetic clonal expansion of F. hepatica
in snails has the potential to reduce diversity of F. hepat-
ica in the definitive host, particularly when the typical
prevalence of infection in snails in the field is low (~5%)
[36–38]. However, it has been shown that, in naturally
infected sheep and cattle, F. hepatica exists as a panmic-
tic population with high levels of diversity in populations
infecting the definitive host [25]. It is not known to what
extent F. hepatica undergoes self and cross-fertilisation
and how this might influence gene flow, or whether F.
hepatica undergoes multiple mating events. Previously,
we have shown that the selfing rate of adult liver fluke
infection in the definitive host is no higher than 2% [25],
which supports the current hypothesis that
cross-fertilization predominates. In future, these clonal
isolates, each identifiable with a unique MLG, constitute
a valuable resource with which to explore gene flow and
reproductive biology of the liver fluke life-cycle stages in
vivo. Each of the six isolates can be tracked through in-
fection in the snail and definitive host. Progeny (eggs
and metacercariae) derived from mating between two
parasite isolates, each with a distinct MLG, can be geno-
typed to identify if cross- or self-fertilization predomi-
nates in the definitive host and explore parasite mating
behaviour.
Variation within and between clonal isolates of Fasciola
hepatica
The fact that each clonal isolate, irrespective of drug re-
sistance status, has a unique and distinct genetic profile
is not surprising given previous work on whole-genome
sequence variation [16]. What is of particular interest
here is phenotypic variation within a clonal isolate. In
naturally infected hosts mature, adult fluke differ consid-
erably in weight, ranging from 40–280 mg, mean 130 ±
4.36 mg (of 205 liver fluke sampled from 26 sheep livers,
data not shown). The impact of the host environment
on parasite development, size and intestinal position has
Table 4 Phenotypic and genotypic characteristics of Fasciola hepatica clonal isolates
No. of whole adult flukes
recovered at PM
Mean weight of adult
flukes ± SD (mg)
Median weight of
adult flukes (mg)
Range of weights recorded
for adult flukes (mg)
No. of adult
flukes genotyped
No. of MLG
observed
FhLivR1 70 108 ± 22 110 30–150 70 1a
165 (T) 83 ± 28 80 20–160 165 1a
FhLivR2 31 86 ± 16.00 90 50–130 31 1b
48 (T) 98 ± 20 100 60–140 48 1b
FhLivR3 35 (T) 102 ± 30 110 40–160 35 1
FhLivS1 15 177 ± 27 180 90–210 15 1
0 (T) – – – – –
FhLivS2 105c 148 ± 25 150 80–230 110 1
0 (T) – – – – –
FhLivS3 112d 129 ± 22 130 80–280 126 1
0 (T) – – – – –
aSame genotype in both animals
bSame genotype in both animals
cPlus an additional 8 partial parasites
dPlus an additional 15 partial parasites
Abbreviations: FhLiv clonal isolate of Fasciola, R resistant to triclabendazole, S susceptible to triclabendazole, (T) treated with 10mg/kg triclabendazole 10 days prior
to PM, PM post-mortem, MLG multilocus genotype based on a panel of 15 microsatellite markers
Table 5 Unique multilocus genotypes for each of the six clonal isolates
Locusa
Clonal isolate Fh_1 Fh_2b Fh_3 Fh_4b Fh_5b Fh_6b Fh_7 Fh_8 Fh_9 Fh_10 Fh_11b Fh_12 Fh_13 Fh_14 Fh_15
FhLivR1 08/10 08/47 07/08 18/20 31/31 33/36 13/13 11/16 07/07 09/11 08/08 07/10 08/11 11/19 14/14
FhLivR2 08/08 08/45 08/08 16/18 24/24 14/33 11/11 11/16 06/07 09/15 07/14 10/15 08/11 17/18 09/14
FhLivR3 11/11 14/19 07/08 16/20 27/32 30/32 11/12 12/12 07/07 09/11 11/12 15/16 08/08 18/18 09/14
FhLivS1 08/08 18/19 07/09 18/23 24/32 31/33 12/12 14/14 06/07 10/16 12/15 10/10 08/08 08/08 09/14
FhLivS2 06/06 08/08 07/08 14/20 27/31 14/16 12/12 11/19 06/07 06/11 08/15 10/10 08/16 17/19 14/14
FhLivS3 10/16 14/15 07/08 16/19 27/30 16/29 13/13 12/12 07/07 11/14 13/13 05/10 08/11 08/08 09/14
aAlleles are identified by the number of microsatellite repeats. The two alleles of each genotype are separated by a /
bLoci where unique genotypes were recorded for each isolate
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been demonstrated for the parasitic nematode
Strongyloides ratti [39]. This study has shown that clonal
liver fluke, with identical MLG, can differ greatly in their
weight (Table 4). This reveals how much the host envir-
onment influences the growth of parasites in the liver;
for example, there is the potential for significant vari-
ation in the time taken to excyst, to exit the intestine
and to enter liver tissue and migrate to the bile ducts.
This variation is important, because size, along with
specific morphological characteristics, is often used as a
means of species-specific identification for Fasciola spp.
[40]. Any/all of these variables could also influence the
sizes of worms recorded. Regardless of what factors in-
fluence phenotypic variation, such variation is an im-
portant consideration when comparing isolates. For
example, here it is not possible to attribute differences
between isolates to resistance or susceptibility to TCBZ,
because variation is apparent even when comparing two
different isolates susceptible (or resistant) to TCBZ. This
highlights that drug resistance studies on highly hetero-
geneous populations need to distinguish between the
impact of standing genetic variation and that of genetic
mutations responsible for conferring resistance traits. It
is worth noting that a mutation in a PGP gene in a small
number of TCBZ-resistant liver fluke in Northern
Ireland [41] was not detected in a larger number of drug
resistant fluke in Australia [42].
Clonal isolates will advance our understanding of drug
resistance in Fasciola hepatica
A lack of understanding of the specific mechanisms in-
volved in drug resistance in F. hepatica raises several im-
portant questions about the origins, heritability and
spread of drug resistance alleles in liver fluke popula-
tions. The clonal isolates reported here allow, for the
first time, genetic crossing experiments between TCBZ-S
and TCBZ-R isolates and supports subsequent genome
mapping approaches that are crucial to addressing these
complex questions in future [21, 43, 44]. A lack of popu-
lation structure and high gene flow in F. hepatica popu-
lations has revealed that TCBZ resistance has the
potential to spread rapidly [36]. The capacity for snails
infected with a single miracidium to shed large numbers
of clonal metacercariae raises the possibility for aggrega-
tion of resistant genotypes on pasture which in turn may
lead to infection of the definitive host with large num-
bers of drug-resistant parasites [25]. Thus, the clonal
amplification of F. hepatica genotypes within G. trunca-
tula demonstrated here highlights the potential for drug
resistance alleles to accumulate rapidly within liver fluke
populations.
Importantly, at a practical level our work provides
valuable insights into interpretation of drug efficacy
studies given the genetic diversity inherent in liver fluke
populations. In the case of FhLivS1 and FhLivS3, critical
tests using the population of parasites from which these
drug sensitive clonal isolates were derived, showed a
TCBZ efficacy of 97% (Table 1). This means that even in
highly TCBZ susceptible populations a proportion of
live, egg producing adult parasites survive and are
retained in the liver post-treatment. This is in contrast
to our observations here with clonal susceptible para-
sites where only one genotype is present and complete
removal of parasites was seen post-TCBZ treatment
(Table 2). It is not known whether the parasites that sur-
vive treatment are TCBZ-susceptible parasites or if they
represent drug-resistant parasites within a population
where TCBZ resistance alleles are at low frequency and
where TCBZ-resistance is emerging. It is interesting to
note that the TCBZ-resistant isolate FhLivR2, was de-
rived from a population of parasites that, based on rigor-
ous faecal egg count reduction test (FECRT) evaluation,
was designated as TCBZ-susceptible [43]. This highlights
the complexities of interpreting the FECRT and identi-
fies the need for sensitive, molecular-based tests to de-
termine the emergence of drug resistance in the field.
Clonal isolates, such as those reported here will signifi-
cantly enhance our ability to map drug resistance
markers by integrating genetic crossing experiments
with genome-wide bioinformatics approaches [20].
Conclusions
A genetic clonal expansion occurs within G. truncatula,
highlighting the potential for amplification of drug re-
sistant genotypes of F. hepatica. Variation in the weight
of parasites within and between clonal isolates and when
comparing isolates that are either susceptible or resistant
to TCBZ represents inherent variation in liver fluke and
cannot be attributed to their resistance or susceptibility
traits. Clonal isolates will facilitate genetic mapping of
drug resistance markers.
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